Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer Institute Cancer immunotherapy has long been dominated…
Browsing: Cancer Research
Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in MIBC Date: February 14, 2025 Author: Dr. Matthew I. Milowsky, MD,…
Introduction: Recent data from the American Society of Clinical Oncology (ASCO) GI Cancers Symposium 2025, as detailed in their educational…
Date: February 8, 2025 The U.S. Food and Drug Administration (FDA) has recently granted approval for datopotamab deruxtecan (DLNK), a…
The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic…
The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
iTeos Therapeutics and GSK revealed promising results from their phase 2 TIGIT trial at the 2024 European Society for Medical…
The interview with Jill O’Donnell-Tormey, PhD, delves into the vital topic of cancer immunotherapy and research, emphasizing the transformative potential…
Health Inequity in Cancer Research: Examining and Uncovering the Disparities by Hala Borno MD By Hala Borno, MD What also…